- Home
- EBC vs RYTM Comparison
EBC vs RYTM Comparison
Compare EBC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBC
- RYTM
- Stock Information
- Founded
- EBC 1818
- RYTM 2008
- Country
- EBC United States
- RYTM United States
- Employees
- EBC N/A
- RYTM N/A
- Industry
- EBC Accident &Health Insurance
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- EBC Finance
- RYTM Health Care
- Exchange
- EBC Nasdaq
- RYTM Nasdaq
- Market Cap
- EBC 3.5B
- RYTM 3.8B
- IPO Year
- EBC 2020
- RYTM 2017
- Fundamental
- Price
- EBC $15.00
- RYTM $61.33
- Analyst Decision
- EBC Buy
- RYTM Strong Buy
- Analyst Count
- EBC 2
- RYTM 12
- Target Price
- EBC $19.25
- RYTM $76.75
- AVG Volume (30 Days)
- EBC 1.2M
- RYTM 632.6K
- Earning Date
- EBC 07-24-2025
- RYTM 05-07-2025
- Dividend Yield
- EBC 3.21%
- RYTM N/A
- EPS Growth
- EBC N/A
- RYTM N/A
- EPS
- EBC N/A
- RYTM N/A
- Revenue
- EBC $457,519,000.00
- RYTM $136,863,000.00
- Revenue This Year
- EBC $25.36
- RYTM $37.88
- Revenue Next Year
- EBC $27.80
- RYTM $72.84
- P/E Ratio
- EBC N/A
- RYTM N/A
- Revenue Growth
- EBC N/A
- RYTM 48.88
- 52 Week Low
- EBC $12.66
- RYTM $35.35
- 52 Week High
- EBC $19.40
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- EBC 44.99
- RYTM 51.78
- Support Level
- EBC $14.61
- RYTM $58.72
- Resistance Level
- EBC $15.13
- RYTM $63.24
- Average True Range (ATR)
- EBC 0.27
- RYTM 2.43
- MACD
- EBC -0.03
- RYTM -0.15
- Stochastic Oscillator
- EBC 28.06
- RYTM 65.51
About EBC Eastern Bankshares Inc.
Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment; Banking business which offers a range of banking lending, savings, and small business offerings, and its wealth management and trust operations.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.